Navigation Links
Cardiovascular Systems Announces Plans for Second Manufacturing Facility - New Facility Expands CSI's Capacity to Produce Peripheral Arterial Disease Systems
Date:10/7/2009

Cardiovascular Systems, Inc. (CSI; Nasdaq: CSII), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, has signed a 10-year lease agreement for a new 46,000-square-foot manufacturing facility in Pearland, Texas. The facility is being built for CSI and will support the production of its Diamondback 360® PAD System, a minimally invasive catheter for treating peripheral arterial disease (PAD), and other products.

St. Paul, MN (PRWEB) October 7, 2009 -- Cardiovascular Systems, Inc. (CSI; Nasdaq: CSII), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, has signed a 10-year lease agreement for a new 46,000-square-foot manufacturing facility in Pearland, Texas. The facility is being built for CSI and will support the production of its Diamondback 360® PAD System, a minimally invasive catheter for treating peripheral arterial disease (PAD), and other products.

"As demand builds for our Diamondback 360°, we need additional manufacturing capacity to accommodate our growth, and multiple facilities to minimize business interruption risk," said Robert J. Thatcher, CSI executive vice president. "We received numerous proposals for facility locations. The State of Texas and City of Pearland put together the most attractive economic package, allowing us to expand quickly into a second facility. We look forward to continuing our partnership with Texas local and state offices, and launching manufacturing operations there."

CSI could hire approximately 250 employees over the course of five years to work at the Texas facility and manufacture the Diamondback 360°. The company will also continue its manufa
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. 8 Ounces a Day of POM Wonderful 100% Pomegranate Juice May Slow Progression of Carotid Intima-Media Thickness (CIMT) in Patients with Elevated Cardiovascular Disease Risk Factors, Study Finds
2. BUSM researchers propose a relationship between androgen deficiency and cardiovascular disease
3. MAQUET Cardiovascular Receives FDA Clearance for MEGA(TM), the Worlds First 8Fr. 50cc Intra-Aortic Balloon Catheter
4. Cardiogenesis Announces Successful Symposium at the Transcatheter Cardiovascular Therapeutics (TCT) Meeting
5. Novel Information about Vulnerable Coronary Artery Plaque to be Presented at Transcatheter Cardiovascular Therapeutics (TCT) 2009
6. Health Leaders Issue Recommendations to Improve Management of a Common, Costly and Misunderstood Cardiovascular Disease: Atrial Fibrillation
7. Dr. Eliscer Guzman, with The Mount Sinai Medical Center, Join Forces to Celebrate the Community Diabetes and Cardiovascular Care Programs Graduation Ceremony on September 16th
8. Finding of genetic region controlling cardiovascular sensitivity to anesthetic propofol
9. Expanded Cardiovascular Care Services on Long Island
10. Lead in bone associated with increased risk of death from cardiovascular disease in men
11. Researchers link inflammatory diseases to increased cardiovascular risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... no stranger to the children of Tanzania. What is ... clinical services, including reliable diagnosis and evidence-based treatments. There ... use in Swahili, a major language of the region. ... University and the University of Georgia (UGA) describe a ... sites in the country and found to be effective ...
(Date:9/30/2014)... 2014 Integrated Medicine Alliance , ... another new medical specialty practice through a unique partnership ... will be located within the company’s Shrewsbury location and ... Isaac Tawfik of American Heart Center, P.C., a highly ... will offer Integrated Medicine Alliance patients top notch cardiovascular ...
(Date:9/30/2014)... September 30, 2014 Glycodrive , ... Nutraceuticals designed to help maximize lean, strong muscle growth ... body’s absorption of glucose has caught the attention of ... main purpose behind Glycodrive is to help the body ... reports Michaels. “Carbs are essential in the muscle-building process, ...
(Date:9/30/2014)... 2014 VisitandCare.com reports that ... gone up more than 79 percent in 2014, marking ... also reported total revenue tripled for its entirety of ... professional strategy has allowed them to partner with ... patient comfort and privacy — with state-of-the-art surgical atmospheres ...
(Date:9/30/2014)... 2014 A group of Americans is headed ... epidemic that, left unchecked, could create a catastrophic, global pandemic. ... to Africa. John Rogers, the Executive Director the Eugene Bell ... fight a disease most think mankind conquered long ago: tuberculosis. ... ago is on the comeback in several countries - what’s ...
Breaking Medicine News(10 mins):Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4Health News:US Delegation Heads to North Korea to Combat Tuberculosis Epidemic 2
... program delivered by over 500 peer volunteers significantly reduces ... researcher Dr. Janusz Kaczorowski told the Canadian Stroke Congress ... Program (CHAP), family physicians in 20 mid-sized Ontario communities ... assessment sessions held at local pharmacies over a 10 ...
... British Columbia (June 7, 2010) Researchers from the ... University of British Columbia today released a comprehensive study ... HIV treatment would create significant benefits for individuals infected ... peer-reviewed mathematical modeling study, published in the research journal ...
... Susan G. Komen for the Cure has appointed V. ... Council. Jordan, a member of the National Academy of ... department of oncology at the Lombardi Comprehensive Cancer Center at ... appointment to the Komen Scientific Advisory Council is reserved for ...
... WASHINGTON, June 7, 2010 Those social drinkers who order ... default "well" liquor. Are they just vodka snobs, who pay ... possibly taste much different than its $6 counterpart? Or is ... claim to taste in America,s favorite hard liquor? ...
... survivors diagnosed later with non-melanoma skin cancer may be ... 15 years, according to research led by St. Jude ... survivors in this Childhood Cancer Survivor Study (CCSS) who ... developed another more aggressive cancer within 15 years, said ...
... in German . Early detection is the ... lump turns out to be a malignant tumor. To find ... biopsy and examine the removed tissue under the microscope. This ... also highly time consuming. Research scientists at the Fraunhofer Institute ...
Cached Medicine News:Health News:A good CHAP reduces rates of heart disease and stroke in communities. 2Health News:Updated HIV therapy guidelines would reduce risk of transmission, save lives, billions in costs 2Health News:Updated HIV therapy guidelines would reduce risk of transmission, save lives, billions in costs 3Health News:Susan G. Komen for the Cure awards grant to Lombardi's V. Craig Jordan 2Health News:Susan G. Komen for the Cure awards grant to Lombardi's V. Craig Jordan 3Health News:Susan G. Komen for the Cure awards grant to Lombardi's V. Craig Jordan 4Health News:Brand preference may be in the drink, not in the head 2Health News:Non-melanoma skin cancer may help identify survivors at increased risk for future cancers 2Health News:Detecting tumors faster 2
(Date:9/30/2014)... -- A study using a relatively new imaging tool, ... the composition of carotid artery disease and has the ... disease, a leading cause of stroke. ... 2010 and May 2012, was featured in the June ... College of Cardiology (JACC) Cardiovascular Interventions. Interventional cardiologist ...
(Date:9/30/2014)... Sept. 30, 2014 BioStructures, LLC has ... Association of Tissue Banks (AATB), it was announced ... Officer. Accreditation follows an intensive nine-month ... trained AATB inspector.  It establishes that the level ... facility meets or exceeds the standards set by ...
(Date:9/30/2014)... 30, 2014 The report based ... Size, Share, Growth and Forecast, 2007 - 2017," elaborated ... USD 20.8 billion in 2012 and is further expected ... a CAGR of 7.3% from 2012 to 2017. ... health purposes, especially to prevent chronic diseases that may ...
Breaking Medicine Technology:New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Biostructures, LLC Earns AATB Accreditation 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4
... Pharma,s eFlow,electronic nebulizer was included in Gilead,s (Nasdaq: ... to the U.S. Food and Drug Administration,(FDA) for ... mg,three times daily). Aztreonam lysine for inhalation, delivered ... people with cystic fibrosis,(CF) who have pulmonary Pseudomonas ...
... large, randomized Phase III trials of VELCADE in front-line, ... ... Mass., Nov. 26 Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM ) today ... studies are scheduled to be,featured at the 49th ASH Annual Meeting ...
Cached Medicine Technology:PARI's eFlow Included in Gilead's NDA Submission for Aztreonam Lysine for Inhalation 2PARI's eFlow Included in Gilead's NDA Submission for Aztreonam Lysine for Inhalation 3New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 2New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 3New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 4New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 5New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma 6
... single use loading unit (SULU), the EEA™ ... staples., ,Immediately after staple formation, a ... excess tissue, thus creating a circular anastomosis. ... handles firmly as far as they will ...
... The Scantibodies Calcitonin Immunoassay is a ... of calcitonin. Two different goat polyclonal antibodies ... affinity chromatography to be specific for well-defined ... the quantitative determination of Calcitonin in human ...
... in the parafollicular C-cells of the thyroid ... The major action of calcitonin is to ... activity, resulting in decreased mobilization of calcium ... evident in conditions associated with high levels ...
Calcitonin RIA Kit...
Medicine Products: